Sublingual vs Subcutaneous Immunotherapy: The Mechanism Behind the Routes

The oral mucosa is a naturally tolerogenic environment because it is constantly exposed to food proteins and commensal microbes that the immune system must not attack. It is populated by specialized antigen-presenting cells, including oral Langerhans-type dendritic cells, that tend to capture antigen and prime regulatory rather than inflammatory responses. When allergen is held under the tongue, these cells take it up and migrate to draining lymph nodes, where they help generate allergen-specific regulatory T cells and a shift toward blocking IgG4 antibodies. This is why sublingual immunotherapy can desensitize rather than sensitize. The mechanism also limits systemic allergen exposure, which contributes to the route's lower systemic-reaction profile compared with injection.

Subcutaneous immunotherapy injects allergen into the tissue beneath the skin, from which it is taken up by dermal and subcutaneous antigen-presenting cells and drained into regional lymph nodes. This route produces a robust systemic immune response, with a strong shift toward allergen-specific blocking IgG4 antibodies and regulatory T cells over time. Because the allergen reaches systemic circulation more directly than via the oral mucosa, the subcutaneous route can drive a vigorous immune modulation but also carries a higher chance of triggering systemic allergic reactions. The cellular endpoint — tolerance — overlaps substantially with the sublingual route, but the immediate exposure dynamics differ, which is why clinic supervision and a post-injection observation period are standard for injections.

Both routes converge on broadly similar immunological endpoints: induction of allergen-specific regulatory T cells, a shift from the allergic Th2 cytokine pattern, and an increase in blocking IgG4 antibodies that compete with IgE for allergen. The magnitude and kinetics can differ — subcutaneous immunotherapy tends to produce a larger and faster rise in systemic IgG4, while sublingual immunotherapy generates strong local mucosal tolerance with a somewhat different systemic signature. These overlapping but not identical immune changes help explain why the routes show broadly comparable clinical efficacy for well-studied allergens like grass while differing in their safety profiles. The shared endpoint is durable tolerance after a sustained multi-year course.

The lower systemic-reaction risk of the sublingual route stems largely from how the allergen is processed. Holding allergen against the oral mucosa engages tolerogenic local cells with comparatively limited and gradual systemic absorption, so the immune system is exposed in a way less likely to trigger a rapid systemic reaction. Sublingual reactions are predominantly mild and local, with no fatalities reported worldwide; in our program fewer than 0.1% of patients have systemic reactions. By contrast, subcutaneous injection delivers allergen more directly to systemic circulation, carrying roughly 0.1% per injection visit and rare documented fatalities. This is a meaningful safety difference, though sublingual therapy is not risk-free and has its own contraindications, such as eosinophilic esophagitis.

Yes. The most common sublingual side effects — itching or tingling of the mouth, tongue, lips, or throat and mild gastrointestinal upset — are local reactions occurring exactly where the allergen contacts the oral mucosa. These reflect the immediate interaction of allergen with mast cells and IgE in the local tissue before tolerance mechanisms take over. They are typically mild and transient, often easing over the first weeks of treatment as the regulatory response develops. The localized nature of these reactions is a direct consequence of the route: because allergen is concentrated at the oral surface rather than distributed systemically, reactions tend to stay local rather than becoming systemic, which aligns with the route's overall safety profile.